This Article Full Text Full Text (PDF) All Versions of this Article: 38/7/2070    most recent STROKEAHA.106.480863v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Botto, N. Articles by Andreassi, M. G. Search for Related Content PubMed PubMed Citation Articles by Botto, N. Articles by Andreassi, M. G. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Substance via MeSH Genetics Home Reference Medline Plus Health Information Heart Surgery Stroke Related Collections Anticoagulants Transient Ischemic Attacks Secondary prevention Embolic stroke Genetics of Stroke Risk Factors for Stroke

(Stroke. 2007;38:2070.)
© 2007 American Heart Association, Inc.

Original Contributions

Prothrombotic Mutations as Risk Factors for Cryptogenic Ischemic Cerebrovascular Events in Young Subjects With Patent Foramen Ovale

Nicoletta Botto, PhD; Isabella Spadoni, MD; Sandra Giusti, MD; Lamia Ait-Ali, MD; Rosa Sicari, MD, PhD, FESC Maria Grazia Andreassi, PhD

From the CNR Institute of Clinical Physiology (N.B., I.S., S.G., L.A.-A., M.G.A.), G. Pasquinucci Hospital, Massa, and the CNR Institute of Clinical Physiology (R.S.), Pisa, Italy.

Correspondence to Dr Maria Grazia Andreassi, CNR Institute of Clinical Physiology, G. Pasquinucci Hospital, Via Aurelia Sud-Montepepe, 54100 Massa, Italy. E-mail andreas{at}ifc.cnr.it

Background and Purpose— Patent foramen ovale (PFO) has been identified as a potential risk factor for cerebrovascular ischemia. Procoagulant mutations may increase the risk and impact the choice of appropriate therapy for secondary prevention. We evaluated the prevalence of the 2 most common genetic risk factors for thromboembolism, factor V Leiden (G1691A) and prothrombin G20210A, in young PFO patients who were referred for percutaneous transcatheter closure of their PFO.

Methods— Ninety-seven patients (50 men; mean±SD age, 40.9±10.0 years) with first-ever cerebrovascular events before the age of 55 years and 160 age-matched control subjects (69 men; mean±SD age, 40.4±10.5 years) were recruited into the study. Factor V Leiden and prothrombin G20210A mutations were detected by using a multiplex allele-specific polymerase chain reaction assay.

Results— The prevalence of subjects carrying at least 1 prothrombotic genotype was significantly higher in the group of PFO patients than in the group of controls (10.3% vs 2.5%; ²=7.2, P=0.008). Two patients (2.1%) versus 1 control subject (0.6%) and 8 cases (8.2%) versus 3 controls (1.9%) were carriers for factor V Leiden and prothrombin G20210A mutations, respectively. After adjustment for other vascular risk factors, the combination of either factor V Leiden or prothrombin G20210A and PFO was associated with a 4.7-fold (95% CI=1.4 to 16.1; P=0.008) increased risk of cerebral ischemia in young patients.

Conclusions— Our results indicate that prothrombotic mutations are important risk factors for cerebral ischemia in young patients with PFO. Screening for thrombotic mutations should be considered in young patients with PFO-related ischemic events.

Key Words: genetics • patent foramen ovale • stroke care • vein thrombosis

This article has been cited by other articles:

				N U Weir An update on cardioembolic stroke Postgrad. Med. J., March 1, 2008; 84(989): 133 - 142. [Abstract] [Full Text] [PDF]